ABEO
Abeona Therapeutics Inc.
Biotechnology
Market Cap$318M
5Y Perf.-92.9%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
ABEO vs RCKT vs KRYS vs CRSP
Revenue, margins, valuation, and 5-year total return — side by side.
RCKT
Rocket Pharmaceuticals, Inc.
Biotechnology
Market Cap$398M
5Y Perf.-81.5%
KRYS
Krystal Biotech, Inc.
Biotechnology
Market Cap$8.75B
5Y Perf.+410.1%
CRSP
CRISPR Therapeutics AG
Biotechnology
Market Cap$5.06B
5Y Perf.-15.1%
ABEO vs RCKT vs KRYS vs CRSP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ABEO | RCKT | KRYS | CRSP |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $318M | $398M | $8.75B | $5.06B |
| Revenue (TTM) | $6M | $0.00 | $417M | $4M |
| Net Income (TTM) | $71M | $-223M | $225M | $-569M |
| Gross Margin | 26.3% | — | 92.8% | -41.7% |
| Operating Margin | -15.4% | — | 42.8% | -134.1% |
| Forward P/E | 5.7x | — | 39.3x | — |
| Total Debt | $25M | $25M | $9M | $395M |
| Cash & Equiv. | $78M | $78M | $496M | $355M |
ABEO vs RCKT vs KRYS vs CRSP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ABEO
RCKT
KRYS
CRSP
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Abeona Therapeutics… (ABEO) | 100 | 7.1 | -92.9% |
| Rocket Pharmaceutic… (RCKT) | 100 | 18.5 | -81.5% |
| Krystal Biotech, In… (KRYS) | 100 | 510.1 | +410.1% |
| CRISPR Therapeutics… (CRSP) | 100 | 84.9 | -15.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ABEO vs RCKT vs KRYS vs CRSP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ABEO leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Krystal Biotech, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
ABEO
Abeona Therapeutics Inc.
The Growth Leader
ABEO carries the broadest edge in this set and is the clearest fit for growth and value.
- 222.9% revenue growth vs CRSP's -90.0%
- Better valuation composite
- 12.2% margin vs CRSP's -138.6%
- 35.8% ROA vs RCKT's -67.5%, ROIC -89.8% vs -63.2%
Best for: growth and value
RCKT
Rocket Pharmaceuticals, Inc.
The Specific-Use Pick
RCKT plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
KRYS
Krystal Biotech, Inc.
The Income Pick
KRYS is the #2 pick in this set and the best alternative if income & stability and growth exposure is your priority.
- beta 1.12
- Rev growth 33.9%, EPS growth 128.0%
- 26.9% 10Y total return vs CRSP's 272.0%
- Lower volatility, beta 1.12, Low D/E 0.8%, current ratio 9.95x
Best for: income & stability and growth exposure
CRSP
CRISPR Therapeutics AG
The Secondary Option
CRSP lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ABEO | 222.9% revenue growth vs CRSP's -90.0% |
| Value | ABEO | Better valuation composite |
| Quality / Margins | ABEO | 12.2% margin vs CRSP's -138.6% |
| Stability / Safety | KRYS | Beta 1.12 vs CRSP's 1.93, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | KRYS | +116.9% vs RCKT's -45.2% |
| Efficiency (ROA) | ABEO | 35.8% ROA vs RCKT's -67.5%, ROIC -89.8% vs -63.2% |
ABEO vs RCKT vs KRYS vs CRSP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
Segment breakdown not available.
FY 2025
ABEO vs RCKT vs KRYS vs CRSP — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKRYSLAGGINGCRSP
Who Leads Where
KRYS leads in 4 of 6 categories
ABEO leads 0 • RCKT leads 0 • CRSP leads 0 • 1 tied
Explore the data ↓CRSPCRISPR Therapeutics AG
0leads
RCKTRocket Pharmaceutical…
0leads
ABEOAbeona Therapeutics I…
0leads
KRYSKrystal Biotech, Inc.
4leads
6 Total Categories
CATEGORYLEADERvs ABEOvs RCKTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KRYS4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
KRYS5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
KRYS6/6
Risk & VolatilityBeta, volatility, and downside exposure
KRYS2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KRYS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
KRYS and RCKT operate at a comparable scale, with $417M and $0 in trailing revenue. ABEO is the more profitable business, keeping 12.2% of every revenue dollar as net income compared to CRSP's -138.6%. On growth, CRSP holds the edge at +68.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ABEOAbeona Therapeuti… | RCKTRocket Pharmaceut… | KRYSKrystal Biotech, … | CRSPCRISPR Therapeuti… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $6M | $0 | $417M | $4M |
| EBITDAEarnings before interest/tax | -$86M | -$232M | $185M | -$535M |
| Net IncomeAfter-tax profit | $71M | -$223M | $225M | -$569M |
| Free Cash FlowCash after capex | -$84M | -$190M | $237M | -$401M |
| Gross MarginGross profit ÷ Revenue | +26.3% | — | +92.8% | -41.7% |
| Operating MarginEBIT ÷ Revenue | -15.4% | — | +42.8% | -134.1% |
| Net MarginNet income ÷ Revenue | +12.2% | — | +53.9% | -138.6% |
| FCF MarginFCF ÷ Revenue | -14.5% | — | +56.9% | -97.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | +31.9% | +68.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -56.5% | +38.7% | +52.5% | +19.0% |
KRYS leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — RCKT and KRYS and CRSP each lead in 1 of 3 comparable metrics.
Valuation Metrics
At 5.7x trailing earnings, ABEO trades at a 87% valuation discount to KRYS's 43.4x P/E.
| Metric | ABEOAbeona Therapeuti… | RCKTRocket Pharmaceut… | KRYSKrystal Biotech, … | CRSPCRISPR Therapeuti… |
|---|---|---|---|---|
| Market CapShares × price | $318M | $398M | $8.7B | $5.1B |
| Enterprise ValueMkt cap + debt − cash | $264M | $345M | $8.3B | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | 5.71x | -1.83x | 43.38x | -8.10x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 39.33x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 49.21x | — |
| Price / SalesMarket cap ÷ Revenue | 54.57x | — | 22.48x | 1440.41x |
| Price / BookPrice ÷ Book value/share | 2.40x | 1.47x | 7.29x | 2.45x |
| Price / FCFMarket cap ÷ FCF | — | — | 46.30x | — |
Evenly matched — RCKT and KRYS and CRSP each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
KRYS leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
ABEO delivers a 53.2% return on equity — every $100 of shareholder capital generates $53 in annual profit, vs $-80 for RCKT. KRYS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to CRSP's 0.21x. On the Piotroski fundamental quality scale (0–9), ABEO scores 6/9 vs CRSP's 1/9, reflecting solid financial health.
| Metric | ABEOAbeona Therapeuti… | RCKTRocket Pharmaceut… | KRYSKrystal Biotech, … | CRSPCRISPR Therapeuti… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | +53.2% | -80.5% | +19.3% | -30.9% |
| ROA (TTM)Return on assets | +35.8% | -67.5% | +17.6% | -24.5% |
| ROICReturn on invested capital | -89.8% | -63.2% | +18.0% | -22.3% |
| ROCEReturn on capital employed | -63.4% | -58.9% | +14.8% | -26.6% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 1 | 5 | 1 |
| Debt / EquityFinancial leverage | 0.16x | 0.09x | 0.01x | 0.21x |
| Net DebtTotal debt minus cash | -$53M | -$53M | -$487M | $40M |
| Cash & Equiv.Liquid assets | $78M | $78M | $496M | $355M |
| Total DebtShort + long-term debt | $25M | $25M | $9M | $395M |
| Interest CoverageEBIT ÷ Interest expense | 19.23x | — | — | — |
KRYS leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
KRYS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KRYS five years ago would be worth $41,919 today (with dividends reinvested), compared to $838 for RCKT. Over the past 12 months, KRYS leads with a +116.9% total return vs RCKT's -45.2%. The 3-year compound annual growth rate (CAGR) favors KRYS at 50.1% vs RCKT's -44.4% — a key indicator of consistent wealth creation.
| Metric | ABEOAbeona Therapeuti… | RCKTRocket Pharmaceut… | KRYSKrystal Biotech, … | CRSPCRISPR Therapeuti… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +8.7% | +6.1% | +20.2% | -2.5% |
| 1-Year ReturnPast 12 months | +9.5% | -45.2% | +116.9% | +53.1% |
| 3-Year ReturnCumulative with dividends | +84.3% | -82.8% | +238.5% | -6.3% |
| 5-Year ReturnCumulative with dividends | -85.0% | -91.6% | +319.2% | -51.3% |
| 10-Year ReturnCumulative with dividends | -90.7% | -91.3% | +2688.5% | +272.0% |
| CAGR (3Y)Annualised 3-year return | +22.6% | -44.4% | +50.1% | -2.2% |
KRYS leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
KRYS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KRYS is the less volatile stock with a 1.12 beta — it tends to amplify market swings less than CRSP's 1.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KRYS currently trades 97.9% from its 52-week high vs RCKT's 49.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ABEOAbeona Therapeuti… | RCKTRocket Pharmaceut… | KRYSKrystal Biotech, … | CRSPCRISPR Therapeuti… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.33x | 1.31x | 1.12x | 1.87x |
| 52-Week HighHighest price in past year | $7.54 | $7.39 | $303.00 | $78.48 |
| 52-Week LowLowest price in past year | $4.00 | $2.19 | $122.80 | $33.50 |
| % of 52W HighCurrent price vs 52-week peak | +76.5% | +49.7% | +97.9% | +66.8% |
| RSI (14)Momentum oscillator 0–100 | 69.4 | 54.4 | 64.3 | 55.5 |
| Avg Volume (50D)Average daily shares traded | 1.2M | 3.5M | 264K | 2.0M |
KRYS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ABEO as "Buy", RCKT as "Buy", KRYS as "Buy", CRSP as "Buy". Consensus price targets imply 194.6% upside for ABEO (target: $17) vs 12.2% for KRYS (target: $333).
| Metric | ABEOAbeona Therapeuti… | RCKTRocket Pharmaceut… | KRYSKrystal Biotech, … | CRSPCRISPR Therapeuti… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $17.00 | $5.00 | $332.75 | $63.00 |
| # AnalystsCovering analysts | 9 | 19 | 17 | 38 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
KRYS leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallKrystal Biotech, Inc. (KRYS)Leads 4 of 6 categories
Loading custom metrics...
ABEO vs RCKT vs KRYS vs CRSP: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ABEO or RCKT or KRYS or CRSP a better buy right now?
For growth investors, Krystal Biotech, Inc.
(KRYS) is the stronger pick with 33. 9% revenue growth year-over-year, versus -90. 0% for CRISPR Therapeutics AG (CRSP). Abeona Therapeutics Inc. (ABEO) offers the better valuation at 5. 7x trailing P/E, making it the more compelling value choice. Analysts rate Abeona Therapeutics Inc. (ABEO) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ABEO or RCKT or KRYS or CRSP?
On trailing P/E, Abeona Therapeutics Inc.
(ABEO) is the cheapest at 5. 7x versus Krystal Biotech, Inc. at 43. 4x.
03Which is the better long-term investment — ABEO or RCKT or KRYS or CRSP?
Over the past 5 years, Krystal Biotech, Inc.
(KRYS) delivered a total return of +319. 2%, compared to -91. 6% for Rocket Pharmaceuticals, Inc. (RCKT). Over 10 years, the gap is even starker: KRYS returned +26. 9% versus RCKT's -91. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ABEO or RCKT or KRYS or CRSP?
By beta (market sensitivity over 5 years), Krystal Biotech, Inc.
(KRYS) is the lower-risk stock at 1. 12β versus CRISPR Therapeutics AG's 1. 87β — meaning CRSP is approximately 66% more volatile than KRYS relative to the S&P 500. On balance sheet safety, Krystal Biotech, Inc. (KRYS) carries a lower debt/equity ratio of 1% versus 21% for CRISPR Therapeutics AG — giving it more financial flexibility in a downturn.
05Which is growing faster — ABEO or RCKT or KRYS or CRSP?
By revenue growth (latest reported year), Krystal Biotech, Inc.
(KRYS) is pulling ahead at 33. 9% versus -90. 0% for CRISPR Therapeutics AG (CRSP). On earnings-per-share growth, the picture is similar: Abeona Therapeutics Inc. grew EPS 165. 2% year-over-year, compared to -49. 1% for CRISPR Therapeutics AG. Over a 3-year CAGR, CRSP leads at 100. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ABEO or RCKT or KRYS or CRSP?
Abeona Therapeutics Inc.
(ABEO) is the more profitable company, earning 1223% net margin versus -165. 7% for CRISPR Therapeutics AG — meaning it keeps 1223% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KRYS leads at 41. 5% versus -161. 9% for CRSP. At the gross margin level — before operating expenses — KRYS leads at 92. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ABEO or RCKT or KRYS or CRSP more undervalued right now?
Analyst consensus price targets imply the most upside for ABEO: 194.
6% to $17. 00.
08Which pays a better dividend — ABEO or RCKT or KRYS or CRSP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is ABEO or RCKT or KRYS or CRSP better for a retirement portfolio?
For long-horizon retirement investors, Krystal Biotech, Inc.
(KRYS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 12)). CRISPR Therapeutics AG (CRSP) carries a higher beta of 1. 87 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KRYS: +26. 9%, CRSP: +289. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ABEO and RCKT and KRYS and CRSP?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ABEO is a small-cap deep-value stock; RCKT is a small-cap quality compounder stock; KRYS is a small-cap high-growth stock; CRSP is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.